BS_0WQJP6ZG
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- overall_survival_months
- 28.97503285151117
- age_years
- 6.222
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.509
- E2F_TARGETS+0.463
- MYC_TARGETS_V1+0.440
- MTORC1_SIGNALING+0.435
- ANGIOGENESIS+0.422
- INTERFERON_ALPHA_RESPONSE+0.417
- G2M_CHECKPOINT+0.415
- INTERFERON_GAMMA_RESPONSE+0.402
- IL6_JAK_STAT3_SIGNALING+0.395
- INFLAMMATORY_RESPONSE+0.390
Top 10 suppressed
- KRAS_SIGNALING_DN-0.318
- PANCREAS_BETA_CELLS-0.271
- MYOGENESIS-0.212
- HEDGEHOG_SIGNALING-0.206
- ESTROGEN_RESPONSE_EARLY-0.143
- APICAL_SURFACE-0.130
- SPERMATOGENESIS-0.101
- NOTCH_SIGNALING-0.032
- BILE_ACID_METABOLISM+0.013
- ESTROGEN_RESPONSE_LATE+0.033
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934921 | — | — | 0.953 |
| 2 | SRR934730 | — | — | 0.941 |
| 3 | SRR934907 | — | — | 0.937 |
| 4 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.937 |
| 5 | SRR934899 | — | — | 0.937 |
| 6 | SRR934895 | — | — | 0.935 |
| 7 | SRR934825 | — | — | 0.934 |
| 8 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.933 |
| 9 | SRR934925 | — | — | 0.932 |
| 10 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.509 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.463 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.435 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.422 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.417 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.415 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.402 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.395 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.382 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.381 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.372 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.359 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.354 | Idelalisib | — uncovered |
| APOPTOSIS | 0.352 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.339 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.316 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.314 | Inavolisib | — uncovered |
| COMPLEMENT | 0.289 | Inavolisib | — uncovered |